论文信息 - A phase I study of the CDK inhibitor dinaciclib (SCH 727965) administered every 3 weeks in patients (pts) with advanced malignancies: Final results. - 字舞流文

A phase I study of the CDK inhibitor dinaciclib (SCH 727965) administered every 3 weeks in patients (pts) with advanced malignancies: Final results.

L. Chirieac | G. Shapiro | S. Rodig | P. Kirschmeier | M. Mita | A. Mita | K. Sankhala | P. Statkevich | K. Small | R. Bannerji | J. Sarantopoulos | J. Cleary | D. Zhang | J. Poon | Y. Jou | J. Moseley